StockData
AtriCure, Inc. logo

AtriCure, Inc. (ATRC) stock

ATRCNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/30893% above fair value
$55.02−0.29 (-0.52%)

Close on Nov 17, 2026Market cap $2.80BP/E 262.0Yield –

Earnings

AtriCure's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 16, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$154.50M
+15.0% on a year earlier
adjusted earnings per share, Q3 FY2026
$0.18
-$0.01 a year earlier
Latest guidance
Raised
Nov 3, 2026 · 4 items

Quarterly results

Revenue and earnings per share from each of AtriCure's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 16, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 3, 2026after the close$154.50M+15.0%$0.08$0.18Release
Q2 FY2026ended Jun 30, 2026Jul 23, 2026after the close$153.60M+12.9%$0.18$0.18Release
Q1 FY2026ended Mar 31, 2026May 5, 2026after the close$141.20M+14.2%$0.00$0.00Release
Q4 FY2025ended Dec 31, 2025Feb 17, 2026after the close$140.50M+13.0%$0.04$0.06Release
Q3 FY2025ended Sep 30, 2025Oct 29, 2025after the close$134.30M+15.9%-$0.01-$0.01Release
Q2 FY2025ended Jun 30, 2025Jul 29, 2025after the close$136.10M+17.0%-$0.13-$0.02Release
Q1 FY2025ended Mar 31, 2025Apr 29, 2025after the close$123.60M+13.5%-$0.14-$0.14Release
Q4 FY2024ended Dec 31, 2024Feb 12, 2025after the close$124.30M+16.7%$0.33$0.08Release
Q3 FY2024ended Sep 30, 2024Oct 29, 2024after the close$115.90M+17.9%-$0.17-$0.17Release
Q2 FY2024ended Jun 30, 2024Jul 30, 2024after the close$116.30M+15.3%$0.17$0.17Release
Q1 FY2024ended Mar 31, 2024May 1, 2024after the close$108.90M+16.5%$0.28$0.25Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

AtriCure's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
revenueGAAPFY2026$606.00M – $610.00M–NewNov 3, 2026
revenueFY2026$602.00M – $610.00M$600.00M – $610.00MRaisedJul 23, 2026
revenueFY2026$600.00M – $610.00M–NewFeb 17, 2026
revenue growthFY2026+12% – +14%–NewJan 12, 2026
adjusted EBITDAnon-GAAPFY2026$91.00M – $94.00M$80.00M – $82.00MRaisedNov 3, 2026
adjusted EBITDAnon-GAAPFY2026$85.00M – $89.00M$80.00M – $82.00MRaisedJul 23, 2026
net income per shareGAAPFY2026$0.21 – $0.27$0.00 – $0.04RaisedNov 3, 2026
net income per shareGAAPFY2026$0.05 – $0.13–NewJul 23, 2026
adjusted earnings per sharenon-GAAPFY2026$0.40 – $0.46$0.09 – $0.15RaisedNov 3, 2026
adjusted earnings per sharenon-GAAPFY2026$0.24 – $0.32$0.00 – $0.04RaisedJul 23, 2026

Guidance vs results

The last range AtriCure gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025adjusted loss per share-$0.26 – -$0.23-$0.11Σ4QAbove range
FY2025Revenue$532.00M – $534.00M$534.50MΣ4QAbove range

Guidance history

Every forecast AtriCure put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 3, 2026adjusted EBITDAFY2026$91.00M – $94.00MRaised
Nov 3, 2026adjusted earnings per shareFY2026$0.40 – $0.46Raised
Nov 3, 2026net income per shareFY2026$0.21 – $0.27Raised
Nov 3, 2026revenueFY2026$606.00M – $610.00MNew
Jul 23, 2026adjusted EBITDAFY2026$85.00M – $89.00MRaised
Jul 23, 2026adjusted earnings per shareFY2026$0.24 – $0.32Raised
Jul 23, 2026net income per shareFY2026$0.05 – $0.13New
Jul 23, 2026revenueFY2026$602.00M – $610.00MRaised
May 5, 2026Adjusted EBITDAFY2026$80.00M – $82.00MReaffirmed
May 5, 2026adjusted earnings per shareFY2026$0.00 – $0.04New
May 5, 2026revenueFY2026$600.00M – $610.00MReaffirmed
Feb 17, 2026adjusted EBITDAFY2026$80.00M – $82.00MNew
Feb 17, 2026adjusted earnings per shareFY2026$0.09 – $0.15New
Feb 17, 2026net earnings per shareFY2026$0.00 – $0.04New
Feb 17, 2026revenueFY2026$600.00M – $610.00MNew
Jan 12, 2026adjusted EBITDAFY2026$80.00M – $82.00MNew
Jan 12, 2026revenue growthFY2026+12% – +14%New
Jan 12, 2026revenueFY2026$600.00M – $610.00MNew
Oct 29, 2025Adjusted EBITDAFY2025$55.00M – $57.00MNew
Oct 29, 2025adjusted loss per shareFY2025-$0.26 – -$0.23New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases AtriCure filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. Results
  6. Results
  7. Results
  8. Results
  9. Results
  10. Results
  11. Update
  12. Results
  13. Results
  14. Results
  15. Results

See a number that looks wrong?